by Kai Herdin | May 8, 2026 | Blog
What makes NAD⁺ so special is that its concentration in human tissues can be influenced both internally and externally, through the body’s own metabolic activity and through dietary supplementation. This makes it especially interesting in the context of aging and...
by Kai Herdin | Apr 29, 2026 | News
NADMED has appointed James Lee as its new Chief Executive Officer, effective from the beginning of May. His appointment supports the company’s next phase of international growth and expansion. Lee brings over 25 years of experience in global pharma and healthcare,...
by Kai Herdin | Mar 31, 2026 | News
We are proud to announce that Dr. Keyue Sun and the Schlegel Lab have been selected as the inaugural recipients of the NADMED Award for their work on metabolic assessment of organ viability in transplantation. Their research tackles a critical question in transplant...
by Kai Herdin | Mar 18, 2026 | News
NADMED has partnered with London-based Altheome Labs to expand access to advanced NAD testing in the UK, marking another step in the company’s international growth. Through this collaboration, NADMED’s CE-marked NAD measurement technology will be integrated into...
by Kai Herdin | Feb 5, 2026 | News
A new abstract, presented at the American Stroke Association’s Conference, explores how NAD and NADP, critical molecules for cellular energy and repair, change in the early days after stroke and what that might mean for recovery. Preliminary findings (n=18) showed: •...